Biowaste Management During Biopharmaceutical Plant Start-Up: From Regulatory Guidance to Verified Inactivation Methods - - BioPharm International

ADVERTISEMENT

Biowaste Management During Biopharmaceutical Plant Start-Up: From Regulatory Guidance to Verified Inactivation Methods


BioPharm International


Had pertinent data relating to chemical inactivation of CHO cells been available at the start-up of our facility, it would have been possible to move quickly and directly to an annual verification of the chosen methods. This paper should supply to other groups valuable in-formation that may be used in justifying the selection and use of similar inactivation procedures in their own facilities.

Mary Heenan, senior scientist, Process Development, Development & Technical Services, The Wyeth BioPharma Campus at Grange Castle, Wyeth Medica Ireland, Grange Castle International Business Park, Clondalkin Dublin 22, Ireland, 01.4696814, Fax: 01.4696896,

REFERENCES

1. Fink R, Moran E. Biosafety for large-scale containment level 1 operations using recombinant DNA technology: No emerging hazards. Applied Biosafety. 2005; 10:30-39.

2. Ebling MJ, Miller S. Validation of a batch type biological waste treatment system. Pharmaceutical Engineering. 1991;11:42-48.

3. Carlson CJ. Biowaste Systems. Pharmaceutical Engineering. 2001;21:70-82.

4. Gregoriades N, Luzardo M, Lucquet B, Ryll T. Heat inactivation of mammalian cell cultures for biowaste kill system design. Biotechnol. Prog. 2003;19:14-20.

5. Block SS, ed. Disinfection, Sterilization, and Preservation. 5th ed. Philadelphia: Lippincott, Williams & Wilkins; 2001.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Compounding Pharmacy Issues Recall, But Challenges FDA Decision
July 22, 2014
AbbVie's Acquisition of Shire Could Save $8 Billion in Taxes
July 21, 2014
AstraZeneca Reveals Design for New Global R&D Center and Corporate Headquarters
July 18, 2014
AbbVie to Acquire Shire for $54.7 Billion
July 18, 2014
Particulate Matter Prompts Baxter's Recall of IV Solutions
July 17, 2014
Author Guidelines
Source: BioPharm International,
Click here